CEO: Anna Brodén
Investment area: Quality of Life
Investment year: 2023
Website: https://www.reccandiagnostics.com
Founded in 2014 by clinicians and researchers from Lund University Hospital, Reccan has developed a highly accurate, non-invasive blood test for the early detection of pancreatic cancer. Designed to integrate seamlessly into diagnostic routes across primary and secondary care, this innovative test enables early identification or exclusion of cancer, significantly improving survival rates. By leveraging clinical expertise and groundbreaking research, Reccan is transforming cancer diagnostics for better patient outcomes.